Welcome to CrystecPharma
CrystecPharma applies the latest supercritical fluid technology to improve the performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.
Applications of our technology include enhancing the dissolution and bioavailability of drugs, optimising release profiles, as well as improving stability and processing characteristics.
Our solutions include the following:
- Crystal and particle engineering
- Stabilisation of therapeutic agents derived from biotechnology
- Polymorph screening
- Improved performance of poorly soluble drugs
- Inhaled therapy
- Taste masking
- Crystallisation seeds
- Residual solvent elimination
CrystecPharma awarded prestigious Newton Fund grant to develop novel treatments for COPD in China
CrystecPharma have been awarded a prestigious grant from the Newton Fund to establish a platform for the treatment of COPD in China, in collaboration with: Dr Omar Usami, Imperial College, Brompton Hospital; Professor Jiwen Zhang, Shanghai Institute of Materia Medica and pharmaceutical company Fudan Zhangjiang.
January 19 2017
Crystec’s Development Director, Dr Lyn Daintree, is to present during a University of Leeds short course: Crystallisation Science and Engineering
Dr Lyn Daintree, Crystec’s Development Director, will be speaking at the upcoming Crystallisation Science and Engineering short course, University of Leeds (16th-18th January 2017). The presentation will focus on ‘Supercritical Fluid Crystallisation - Designed Particles for Optimised Formulations'.
January 11 2017
Crystec’s Chief Scientist, Professor Peter York, recognised among the “TRUE GIANTS” of Pharmaceutical Sciences
Professor Peter York, Crystec’s Chief Scientist, has been honoured by the Journal of Pharmaceutical Sciences with the release of a dedicated issue
January 3 2017